계정 가입
이미 존재한 계정
가입을 클릭하여 코인타임의 <a class="underline" href="#term-of-service">서비스 약관</a> 과 a class="underline" href="#privacy-policy">개인정보 보호 정책</a> . 에 동의함.
email 로 로그인
email 로 가입
사용자 이메일
수신함을 확인하세요
중의 링크를 통해 로그인 하세요
중의 링크를 통해 가입 하세요
PDS Biotechnology Corporation
company
About
PDS Biotechnology Announces Treatment of First Patient with PDS0101.
- 11 - 50
Highlights
Details
- Last Funding Type
- Post-IPO Debt
- Last Funding Money Raised
- $25M
- Industries
- Biotechnology,Health Care,Pharmaceutical
- Founded date
- Jan 1, 2005
- Number Of Employee
- 11 - 50
- Operating Status
- Active
PDS Biotechnology Corporation is a biopharmaceutical company. It develops immunotherapies for cancer and other infectious diseases. It develops products to prevent and treat cervical, ovarian, melanoma, leukemia, pancreatic, oral, multiple myeloma, anal, vulvar, and penile cancers. The company offers PDS0101, a treatment for HPV-related cancers; PDS0102, a pandemic influenza vaccine; and PDS0103, a line of immunotherapy products for non-viral cancers.PDS Biotechnology Corporation was founded in 2005 and is headquartered in North Brunswick, New Jersey.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$25M
PDS Biotechnology Corporation has raised a total of
$25M
in funding over 2 rounds. Their latest funding was raised on
Aug 24, 2022 from a Post-IPO Debt round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 24, 2022 | Post-IPO Debt | $25M | 1 |
Horizon Technology Finance
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
PDS Biotechnology Corporation is funded by 1 investors.
Horizon Technology Finance
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Horizon Technology Finance
|
Yes | Post-IPO Debt |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
